Angiotech and Orthovita announce commercial launch of Vitagel(TM)
VANCOUVER, BC and MALVERN, PA, Jan. 11 /PRNewswire-FirstCall/ -- Angiotech
Pharmaceuticals, Inc. (NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP) and Orthovita, Inc. (NASDAQ:VITA) today announced that the companies have begun the official
commercial launch of Vitagel(TM). Orthovita has initiated distribution through
its 40 direct sales representatives and roughly 20 independent distributors. The direct representatives will have a launch base that extends over 500
hospitals. As part of the Cohesion consolidation, Angiotech expects a full
transfer of production capabilities from the Palo Alto facility to Orthovita's
Malvern facility to be complete by Q3:05.
"We look forward to getting this product into the hands of the orthopedists,"
said Antony Koblish, CEO of Orthovita. "We believe that Vitagel(TM) is not only
a novel product, but has excellent sales synergies with our biomaterials
franchise." "Orthovita has a specialized sales force focused on the spine and orthopedic
biomaterials space," said William Hunter, President and CEO of Angiotech. "We
anticipate that Vitagel(TM) will be a useful and vital tool for orthopedists as
they become increasingly familiar with the product." Vitagel(TM) Surgical Hemostat is designed for use in cardiovascular,
orthopedic, urologic and general surgery indications to control bleeding. Vitagel(TM) differs from other competitors in that it uses autologous (a
patient's own) blood as opposed to products from pooled donor blood, thus
reducing the risk of transmission of diseases associated with donor blood. Vitagel(TM) has been shown in randomized, controlled studies to reduce blood
loss by over 50% during spinal surgeries. CE mark approval for Vitagel(TM) was
granted in September 1998. In June 2000, Vitagel(TM) received approval from the
United States Food and Drug Administration, or FDA, to market Vitagel(TM) in
the U.S.
Orthovita is a specialty orthopedics company that develops and markets
synthetic biomaterials for use in fracture repair and orthopedic trauma, spine
surgery including spinal fusion, repair of osteoporosis-related fractures of
the spine and other orthopedic applications. Orthovita's products represent
fully synthetic alternatives to the use of autograft or cadaver-derived bone
material in orthopedic and spine surgery. To find out more about Orthovita,
Inc., please visit our website at http://www.orthovita.com/.
Vancouver-based Angiotech Pharmaceuticals, Inc., a specialty pharmaceutical
company focusing on drug-coated medical devices and biomaterials, is dedicated
to enhancing the performance of medical devices and biomaterials through the
innovative uses of pharmacotherapeutics. To find out more about Angiotech
Pharmaceuticals, Inc., please visit our website at http://www.angiotech.com/.
Statements contained herein that are not based on historical or current fact,
including without limitation statements containing the words "anticipates,"
"believes," "may," "continue," "estimate," "expects," "may" and "will" and
words of similar import, constitute "forward-looking statements" within the
meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such
forward-looking statements involve known and unknown risks, uncertainties and
other factors that may cause the actual results, events or developments to be
materially different from any future results, events or developments expressed
or implied by such forward-looking statements. Such factors include, among
others, the following: general economic and business conditions, both
nationally and in the regions in which each Company operates; technology
changes; competition; changes in business strategy or development plans; the
ability to attract and retain qualified personnel; existing governmental
regulations and changes in, or the failure to comply with, governmental
regulations; liability and other claims asserted against either Company; and
other factors referenced in either Company's respective filings with the United
States Securities and Exchange Commission or the Canadian securities
regulators. Given these uncertainties, readers are cautioned not to place undue
reliance on such forward-looking statements. Nether Company assumes the
obligation to update any forward-looking statements.
CONTACTS:
Todd Young, Angiotech Pharmaceuticals (Analysts & Investors),
(604) 221-7676 ext. 6933
Rui Avelar, Angiotech Pharmaceuticals, Inc. (Analysts),
(604) 221-7676 ext. 6996
Eric Starkman, Starkman & Associates (Media), (212) 252-8545 ext. 12
Joseph M. Paiva, Orthovita, Inc., (610) 640-1775 or (800) 676-8482
DATASOURCE: Angiotech Pharmaceuticals, Inc.; Orthovita, Inc.
CONTACT: Todd Young, Angiotech Pharmaceuticals (Analysts & Investors), (604) 221-7676 ext. 6933; Rui Avelar, Angiotech Pharmaceuticals, Inc.
(Analysts), (604) 221-7676 ext. 6996; Eric Starkman, Starkman & Associates (Media), (212) 252-8545 ext. 12; Joseph M. Paiva, Orthovita, Inc., (610) 640-1775 or (800) 676-8482
|